Trends & Viral SBS Sports · 2026-11-10

US Mandates Vision-Loss Warnings on Wegovy and Ozempic, Fueling Safety Concerns in South Korea

Key Points
  • The US FDA has ordered drugmakers to add explicit warnings about non-arteritic anterior ischemic optic neuropathy (NAION), a condition causing sudden and irreversible vision loss, to all GLP-1 weight-
  • The move has sparked attention in South Korea, where suspected vision impairment linked to GLP-1 drugs was previously raised during a 2024 parliamentary audit amid surging domestic use.
  • Regulators enacted the mandate to prevent misuse and inform patients as GLP-1 medications boom globally, despite the precise mechanism behind optic nerve damage remaining under investigation.
Summary The global craze surrounding GLP-1 weight-loss medications like Wegovy and Ozempic has encountered a significant medical cautionary note. Following a mandate from the U.S. Food and Drug Administration (FDA), drug manufacturers are now required to place explicit warning labels on all marketed GLP-1 receptor agonists regarding the risk of non-arteritic anterior ischemic optic neuropathy (NAION)—a rare but severe condition often referred to as an 'eye stroke.' NAION occurs when blood flow to the optic nerve is abruptly restricted or blocked. The condition strikes suddenly and without accompanying pain, causing rapid vision loss. Because there is currently no established cure or effective treatment, NAION frequently leads to permanent vision impairment or irreversible blindness. The FDA's directive follows medical research published in 2024 demonstrating that patients with diabetes and obesity who took semaglutide faced a four- to seven-fold higher risk of developing NAION compared to those who did not take the drug. The European Medicines Agency (EMA) has likewise highlighted this risk, recommending precautionary labeling. The warning has prompted serious discussions in South Korea, where the appetite for novel obesity treatments and aesthetic weight-loss solutions has surged in recent years. South Korean regulatory and parliamentary scrutiny had already intensified after a December 2024 National Assembly audit disclosed a suspected case of vision loss following the administration of a GLP-1 obesity treatment domestically. As Wegovy and related drugs rapidly gained popularity among the Korean public, concerns mounted over aggressive off-label marketing, casual cosmetic use, and inadequate awareness of severe adverse effects. While the FDA emphasized that the exact physiological mechanism through which GLP-1 medications compromise optic nerve blood flow remains unproven, regulators made the warning label mandatory to curb medication misuse and ensure that patients and healthcare providers can make informed decisions before prescribing these blockbuster lifestyle drugs. In South Korea, health advocates and consumers are now watching closely to see whether domestic health authorities will mirror the U.S. and European mandates with enhanced local warnings.
Sponsored · Ad